Ascentage Pharma Group International
AAPG24.520USD
+0.330+1.36%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
0.00Marktkapitalisierung
--KGV TTM
mehr Informationen über Ascentage Pharma Group International Unternehmen
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
Ascentage Pharma Group International Informationen
BörsenkürzelAAPG
Name des UnternehmensAscentage Pharma Group International
IPO-datumOct 28, 2019
CEOYang (Dajun)
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
Geschäftsjahresende- -
Addresse68 Xinqing Road, Suzhou Industrial Park
StadtSUZHOU
BörseNASDAQ OMX - NASDAQ BASIC
LandChina
Postleitzahl- -
Telefon
Websitehttps://www.ascentage.cn/
BörsenkürzelAAPG
IPO-datumOct 28, 2019
CEOYang (Dajun)
Führungskräfte von Ascentage Pharma Group International
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Tue, Jan 20
Aktualisiert: Tue, Jan 20
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
XY Capital Ltd.
0.02%
Point72 (DIFC) Ltd
0.02%
NEOS Investment Management, LLC
0.01%
Citadel Advisors LLC
0.01%
Andere
99.94%
Aktionäre
Aktionäre
Anteil
XY Capital Ltd.
0.02%
Point72 (DIFC) Ltd
0.02%
NEOS Investment Management, LLC
0.01%
Citadel Advisors LLC
0.01%
Andere
99.94%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
0.06%
Hedge Fund
0.01%
Andere
99.93%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
23
89.21K
0.29%
--
2025Q3
23
89.21K
0.29%
+6.09K
2025Q2
16
82.77K
0.27%
-154.43K
2025Q1
6
237.19K
0.00%
+237.19K
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
XY Capital Ltd.
18.12K
0.02%
+12.53K
+224.15%
Sep 30, 2025
Point72 (DIFC) Ltd
17.93K
0.02%
-2.96K
-14.17%
Sep 30, 2025
NEOS Investment Management, LLC
10.38K
0.01%
-5.11K
-32.98%
Sep 30, 2025
Citadel Advisors LLC
9.65K
0.01%
+9.65K
--
Sep 30, 2025
UBS Financial Services, Inc.
18.34K
0.02%
+10.99K
+149.35%
Sep 30, 2025
Mirae Asset Global Investments (USA) LLC
2.46K
0%
+2.46K
--
Sep 30, 2025
Tower Research Capital LLC
829.00
0%
+829.00
--
Sep 30, 2025
Geode Capital Management, L.L.C.
361.00
0%
--
--
Nov 30, 2025
Osaic Holdings, Inc.
220.00
0%
+220.00
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Tema Oncology ETF
0.43%
Invesco Golden Dragon China ETF
0%
Tema Oncology ETF
Anteil0.43%
Invesco Golden Dragon China ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
